Efficacy of autologous peripheral blood stem cell (PBSC) harvest and engraftment after ablative chemotherapy in pediatric patients

Paul R. Haut, Susan Cohn, Elaine Morgan, Maureen Hubbell, Karina Danner-Koptik, Marie Olszewski, Mary Schaff, Morris Kletzel

Research output: Contribution to journalArticlepeer-review

9 Scopus citations

Abstract

Thirty-five pediatric patients, 1-16 years of age (median 6.3 years), with neoplastic solid tumors (n=32) or acute leukemia (n=3) underwent peripheral blood stem cell (PBSC) harvest and transplantation at Children's Memorial Hospital between September 1992 and April 1997. A median of four phereses were performed on each patient. Blood samples from 34 of the 35 patients were harvested through existing double-lumen central catheters, using either a Fenwal CS-3000 or COBE Spectra pheresis machine. The pheresis procedures were well tolerated overall. A median of 3.7×106/kg CD34+ cells were infused (range, 0.2-15.5×106/kg), and all patients engrafted. The median time to an absolute neutrophil count >500/μL was 13 days (range, 9-44 days) and to a platelet count >20,000/μL was 21 days (range, 9-210 days). Two patients died from transplant-related complications. Patients were discharged from the hospital after a median of 22 days (range, 15-64 days). Twenty of the 35 patients are alive, 17 of whom remain disease-free with a median follow-up of 1144 days. According to this study, PBSCs can be successfully harvested and re-infused for marrow reconstitution after myeloablative therapy in children for a variety of pediatric malignancies with low morbidity and mortality.

Original languageEnglish (US)
Pages (from-to)38-42
Number of pages5
JournalBiology of Blood and Marrow Transplantation
Volume4
Issue number1
DOIs
StatePublished - 1998

Keywords

  • PBSC
  • Pediatrics
  • Transplant

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Fingerprint Dive into the research topics of 'Efficacy of autologous peripheral blood stem cell (PBSC) harvest and engraftment after ablative chemotherapy in pediatric patients'. Together they form a unique fingerprint.

Cite this